Status:

RECRUITING

Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients

Lead Sponsor:

Tianjin Medical University General Hospital

Conditions:

Sleep Disturbance

Eligibility:

All Genders

20-65 years

Phase:

NA

Brief Summary

To explore the effects of esketamine combined with remimazolam on postoperative sleep disturbance and anxiety in surgical patients undergoing gastroenteroscopies

Detailed Description

Postoperative sleep disturbance (PSD) occur in the form of sleep deprivation, circadian rhythm disturbance, and structural abnormalities, and have a high incidence in patients undergoing surgery. Post...

Eligibility Criteria

Inclusion

  • Age 20-65 years old;
  • ASA classification is grade I-III;
  • Elective surgery is proposed
  • BMI of 19-30 kg/m2;
  • Patients who agreed to enroll in this study voluntarily

Exclusion

  • Those who are known to be allergic to the drug ingredients in this study and their allergic constitution;
  • Allergic history of general anesthesia drugs, opioid drugs, non-steroidal drugs;
  • History of neurological diseases; History of chronic pain; Drug and alcohol addiction; A long history of opioid use; Opiates were given 48 hours before surgery;
  • ASA rating of IV or V;
  • Coronary heart disease, bronchial asthma, severe hypertension, severe blood system dysfunction, liver and kidney function, electrolyte abnormalities;
  • History of gastrointestinal disease (peptic ulcer, Crohn's disease, ulcerative colitis);
  • Respiratory insufficiency, respiratory failure;
  • Patients who refused to use intravenous PCA for analgesia;
  • Pregnant or lactating women;
  • BMI\<18 kg/m2 or BMI\>30kg/m2;
  • Poor compliance, unable to complete the experiment according to the study plan;
  • Participants who have participated in clinical trials of other drugs within the last 4 weeks;
  • Any circumstances deemed unsuitable for inclusion by the researcher for any reason.

Key Trial Info

Start Date :

December 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 10 2024

Estimated Enrollment :

400 Patients enrolled

Trial Details

Trial ID

NCT06108830

Start Date

December 1 2023

End Date

December 10 2024

Last Update

September 4 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Tianjin Medical University General Hospital

Tianjin, China, 300052